NEW YORK – Swedish firm Affibody launched a new Phase II study of its HER2 PET imaging agent tezatabep matraxetan to identify metastatic breast cancer patients who may respond to treatment with Daiichi Sankyo and AstraZeneca's antibody-drug conjugate Enhertu (trastuzumab deruxtecan), the company announced Tuesday.

Please register for free here and read more